NCT05583604Available不适用
Managed Access Programs for AIN457, Secukinumab
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
详细描述
CAIN457M2002M - Available - Managed Access Program (MAP) Cohort Treatment Plan CAIN457M2002M to provide access to Secukinumab for adult and adolescent patients with Hidradenitis Suppurativa (HS)
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An independent request should be received from a licensed physician (in some instances from Health Authorities, Institutions or Governments).
- •The patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options.
- •The patient is not eligible or able to enroll in a Novartis clinical trial or continue participation in a Novartis clinical trial.
- •There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
- •The patient must meet any other medical criteria established by the medical experts responsible for the product or by the Health Authority in a country (as applicable).
- •Provision of the product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program.
排除标准
- 未提供
研究者
相似试验
Available
不适用
Managed Access Programs for SEG101, CrizanlizumabSickle Cell DiseaseNCT03720626Novartis Pharmaceuticals
Unknown
不适用
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active DiseaseMultiple SclerosisNCT04540861Novartis Pharmaceuticals
No Longer Available
不适用
Canakinumab MAP in COVID-19 Pneumonia With CRSCytokine Release Syndrome in COVID-19-induced PneumoniaNCT04476706Novartis Pharmaceuticals
Available
不适用
Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous UrticariaChronic Spontaneous UrticariaNCT05170724Novartis Pharmaceuticals
No Longer Available
不适用
177Lu-PSMA-617 Managed Access Program for mCRPC PatientsMetastatic Castration-resistant Prostate Cancer (mCRPC)NCT04825652Advanced Accelerator Applications